Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients

Chest

Volumn 117, Issue 2, 2000, Pages 365-373

  De Vita, Ferdinando ^a,b   Orditura, Michele ^a   Galizia, Gennaro ^a   Romano, Ciro ^a   Roscigno, Annarita ^a   Lieto, Eva ^a   Catalano, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Interleukin 10 serum levels; Non small cell lung cancer; Prognosis

Indexed keywords

INTERLEUKIN 10;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033994349     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.2.365     Document Type: Article

References (29)

1. 1 Hellstrom KE, Hellstrom I, Brown JP. Unique and common tumor-specific transplantation antigens of chemically-induced mouse sarcomas. Int J Cancer 1978; 21:317-322
2. 2 Lynch DH, Miller RE. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Eur J Immunol 1991; 21:1403-1410
3. 3 Barsoum AL, Coggin JH. Immunogenicity of a soluble partially purified oncofetal antigen from murine fibrosarcoma in syngeneic mice. J Biol Response Mod 1989; 8:579-592
4. 4 Pawelec G, Zeuthen J, Kiessling R. Escape from host-antitumor immunity. Crit Rev Oncog 1997; 8:111-141
5. 5 Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993; 60:247-267
6. 6 Chouaib S, Asselin Paturel C, Mami Chouaib F, et al. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18:493-497
7. 7 Oppenheim J, Fujiwara H. The role of cytokines in cancer. Cytokine Growth Factor Rev 1996; 7:279-288
8. 8 Venetsanakos E, Beckman I, Bradley J, et al. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 1997; 75:1826-1830
9. 9 Morisaki T, Katano M, Ikubo A, et al. Immunosuppressive cytokines (IL-10, TGF-beta) genes expression in human gastric carcinoma tissues. J Surg Oncol 1996; 63:234-239
10. 10 Spellman JE, Gollnick SO, Zhang PJ, et al. Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumour bed. Surg Oncol 1996; 5:237-244
11. 11 Romagnani S. Lymphokine production by human T cells in disease states. Ann Rev Immunol 1994; 12:227-257
12. 12 Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Ann Rev Immunol 1993; 11:165-190
13. 13 de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-924
14. 14 Kazuyuki T, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T cell growth. Blood 1993; 81:2964-2971
15. 15 Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996; 56:5499-5505
16. 16 Gotlieb WH, Abrams J, Watson JM, et al. Presence of interleukin (IL)-10 in the ascites of patients with ovarian and other intra-abdominal cancer. Cytokine 1992; 4:385-390
17. 17 Dummer W, Bastian BC, Ernst N, et al. Interleukin-10 production in malignant melanoma : preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996; 66:607-610
18. 18 Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 production by by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55:96-101
19. 19 Smith DR, Kunkel SL, Burdick MD, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994; 145:18-25
20. 20 Huang M, Wang J, Lee P, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995; 55:3847-3853
21. 21 Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82:2169-2174
22. 22 Wojciechowska Lacka A, Matecka Nowak M, Adamiak E, et al. Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma 1996; 43:155-158
23. 23 Fortis C, Foppoli M, Gianotti L, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996; 104:1-5
24. 24 Garfinkel A. Cancer statistics and trends. In: Holleb AI, Fink DJ, Murphy GP, eds. American Cancer Society textbook of clinical oncology. Atlanta, GA: American Cancer Society, 1991; 2-9
25. 25 Dubinett SM, Kradin RL. Cytokine immunotherapy of non-small cell lung cancer. Reg Immunol 1993; 5:232-242
26. 26 Ralph P, Nakoinz I, Sampson-Johannes A, et al. IL-10, T-lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992; 148:808-814
27. 27 Spagnoli GC, Juretic A, Schultz-Thater E, et al. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. Cell Immunol 1993; 146:391-405
28. 28 Avradopoulos K, Mehta S, Blackinton D, et al. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol 1997; 4:184-190
29. 29 Gianotti L, Fortis C, Braga M, et al. Radical oncologic surgery affects the circulatory levels of interleukin 10. J Surg Oncol 1997; 66:244-247